A system and a method for evaluating a longitudinal evolution of a quantitative biomarker measured for a biological object include receiving longitudinal measurements of the quantitative biomarker for the biological object. A statistical parameter, which characterizes a variability of the acquisition technique being used, is calculated for each measurement. The calculated statistical parameter is used for each obtained biomarker value for generating synthetic data having a distribution which follows the statistical distribution of possible values for the biomarker. The sampled values are fitted by using a fitting function for each bootstrapping fitting. A fitting parameter of the fitting function is extracted for each fitting. The longitudinal evolution of the quantitative biomarker is evaluated by statistically comparing the extracted fitting parameters against a reference value.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
2.
METHOD FOR ACQUIRING AND RECONSTRUCTING IMAGES OF A HEART IN FREE BREATHING, SYSTEM
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX (France)
FONDATION BORDEAUX UNIVERSITÉ (France)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Suisse)
Inventeur(s)
Stuber, Matthias
Bustin, Aurélien
Cochet, Hubert
Abrégé
A Method for reconstructing an image of a patient's heart from a magnetic resonance imaging device generating a magnetic field, includes acquisition of the electrical activity of the patient's heart; generation of an MRI sequence and acquisition of a 2D black blood image; generation of an MRI sequence and acquisition of a 2D bright blood image; application of a non-rigid registration algorithm to each subset of black blood images for each heart section; application of a non-rigid registration algorithm to each subset of bright blood images for each heart section; generation of a set of 2D images for each section plane, each image corresponding to a combination made between each pair of black blood and bright blood images.
G06T 11/60 - Édition de figures et de texteCombinaison de figures ou de texte
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 5/366 - Détection de complexes QRS anormaux, p. ex. élargissement
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés basés sur les caractéristiques
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX (France)
FONDATION BORDEAUX UNIVERSITÉ (France)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Suisse)
Inventeur(s)
Maillot, Aurélien
Bustin, Aurélien
Cochet, Hubert
Stuber, Matthias
Abrégé
A method for determining an optimal characteristic set of at least one characteristic parameter of an image acquisition sequence of an area to be imaged by magnetic resonance configured to substantially cancel out medical signals from at least one predetermined tissue, the method including the selection, computer-implemented, of an optimal characteristic image having a greater number of pixels of intensity less than or equal to a given intensity threshold among a plurality of characteristic images of a characteristic area of the area to be imaged generated by respective acquisition sequences having distinct respective sets of at least one characteristic parameter, the optimal characteristic set being the characteristic set of the acquisition sequence by which the optimal characteristic image was generated.
This disclosure describes a method for de novo bottom-up assembly and rational design of allosteric biosensors with programmable input-output behaviors that respond to soluble factors selectively enriched in tumors and trigger co-stimulation and cytokine signals. The disclosed method of effective mechanical coupling and biosensor signaling potency correlates with anti-tumor function. This disclosure provides synthetic biosensors with custom-built sensing and responses for basic and translational cell engineering applications.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
5.
METHOD AND SYSTEM FOR CHARACTERIZING A SPATIAL PATTERN FOR A MICROSTRUCTURAL PROPERTY OF A BIOLOGICAL TISSUE
A system and a method for characterizing a spatial distribution of a tissue microstructural property from quantitative imaging data. A property map for a tissue of a biological object is acquired. An intensity of voxels of the property map represents a measured value V of the microstructural property. A distance d is determined for each of a set of voxels from a center of interest, to associate each voxel to a measured value V and a determined distance d. A function f is fitted for the voxels with a set of fitting parameters and the values of each fitting parameter is determined from the fit. Then, the value of at least one of the fitting parameters is output.
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
6.
ANTISENSE TRANSFER VECTORS AND METHODS OF USE THEREOF
The present disclosure describes a next-generation antisense transfer vector along with methods for a high titer lentivirus production, allowing efficient transduction of T cells with a constitutively expressed tumor-targeting receptor along with the activation-induced expression of various gene cargos. The disclosed antisense transfer vector and the methods can reduce virus production costs as well as enhance the efficacy and safety of next-generation CAR- or TCR-T cells reaching the clinic.
A system and a method for detecting and quantifying a tissue alteration of a biological object. The method comprises the following steps: acquiring multiple quantitative maps of the biological object, wherein each of the multiple quantitative maps is a quantitative map of a different physical tissue property of the biological object; combining the acquired quantitative maps into a combined quantitative map (CQM); and calculating a deviation map by comparing the CQM to a normative atlas configured for providing expected values for the CQM.
The present disclosure relates to methods and compositions to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified lymphocytes such as human T lymphocytes. The disclosure provides compositions comprising genetically-modified lymphocytes that express at least two transgene(s) having the ability to modulate the immune system and the innate and adaptive immune response.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
9.
IMPLANTABLE INTERNAL DRAINAGE DEVICE AND SYSTEM FOR EDEMAS
Disclosed are a fluid drainage devices and methods of use for drainage of edematous tissues of a patient. The devices include an inlet catheter comprising a plurality of lumens configured to receive fluid from the edematous tissues, wherein the plurality of lumens run axially parallel in the inlet catheter; an outlet catheter configured to be anchored at a sink; an implantable pump coupled to the inlet catheter and the outlet catheter, the pump having a rotating portion including a permanent magnet, the rotating portion configured to rotate in response to a magnetic force external to the patient to move fluid from the inlet of the inlet catheter to the second end of the outlet catheter; and an external controller configured to transcutaneously couple to the permanent magnet of the rotating portion to apply the magnetic force to the implantable pump.
The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The invention relates to chimeric antigen receptors (CARs) targeting a cancer-associated antigen and their use for treatment of a tumor or cancer. In particular, the invention provides compositions and methods for treating diseases associated with the antigen NGcGM3. The invention also relates to CARs specific to NGcGM3, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to NGcGM3.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention describes a method for obtaining lymphoid cells having a desired phenotype for adoptive transfer therapies useful for the treatment of cancer. Especially, this invention is related to strategies for inducing preferential signaling through the intermediate affinity IL-2 receptor in order to expand the cells with a desired central memory phenotype. The method of the present invention is useful for obtaining tumor-infiltrating lymphocytes, TCR or chimeric antigen receptor engineered T cells for the treatment of cancer.
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (Suisse)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Suisse)
Inventeur(s)
Ritter, Gerd
Dunn, Steven
Abrégé
Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-β1 are provided, recognizing human and mouse TGF-β1, particularly that preferentially bind TGF-β1, including which do not recognize or bind TGF-β2 or TGF-β3. Humanized and variant antibodies provided are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and/or combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Particular antibodies are exemplified herein, including antibodies 13A1-2A, 13A1-2B, 13A1-2C, 13A1-2D, 13A1-2E, 13A1-2F, 13A1-2G, 13A1-2H, 13A1-2I, 13A1-2J, 13A1-AF, 13A1-AG, 13A1-AH, 13A1-BF, 13A1-BG, 13A1-BH, 13A1-CF, 13A1-CG, 13A1-CH, 13A1-DF, 13A1-DG, 13A1-DH, 13A1-EF, 13A1-EG and 13A1-EH.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (Suisse)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Suisse)
Inventeur(s)
Ritter, Gerd
Dunn, Steven
Abrégé
Antibodies, particularly humanized antibodies and variant antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Humanized and variant antibodies are provided which specifically recognize and neutralize TGF-β3 and are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens, and in fibrotic conditions. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy and in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by antibodies hereof, including antibodies 1901-1A, 1901-1B, 1901-1C and 1901-1D whose sequences are provided herein.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Provided herein are compounds (e.g., compounds of Formulae (I), (II), and (III)) which are anti-fungal agents and can be used in the treatment of diseases, including infectious diseases. The invention provides methods of treating diseases in a subject (e.g., infectious diseases such as fungal infections), and methods of killing or inhibiting the growth of fungi in or on a subject or biological sample. The compounds may be used in subjects, in clinical settings, or in agricultural settings.
C07C 335/40 - Thiourées, c.-à-d. composés contenant l'un des groupes: les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes thiourée ou isothiourée liés de plus à des hétéro-atomes
The application provides genetically modified T cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-l. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, including but not limited to genetically engineered cells, and pharmaceutical compositions. The application further provides the use of such modified T cell receptors (TCRs) and related compositions for cancer immunotherapy (e.g., adoptive cell therapy).
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
18.
Implantable internal drainage device and system for edemas
The invention relates to a medical fluid drainage device for drainage of edematous tissues comprising at least one pumping element (1, 23, 33), having an inlet and an outlet, at least one outlet member (2) having at least one lumen, connected directly or indirectly to the outlet of said pumping element and connecting said pumping element to a body cavity or to a vessel or to a subcutaneous area, and at least one inlet member (3) connected to said inlet of said pumping element and providing fluidic connection between said edematous tissue and said pumping element, and characterized in that the inlet member comprises at least two inlet lumens (4, 5, 6) connected in parallel to said inlet of said pumping element, each of said lumens (4, 5, 6) contains at least one fluid access region, wherein each fluid access region (8, 9, 10) being adapted to allow simultaneous edematous fluid entry from distinct regions of said edematous tissue.
Salmonella bacteria in the gut of subjects, thereby providing immune exclusion and limiting bacterial entry, therefore reducing mucosal and systemic infection.
This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.
Selectively exciting bulk protons in certain tissue components, e.g. water, while suppressing the excitation of others, e.g. fat, can lead to images with better contrast for desired features. The invention provides binomial, off-resonance RF excitation pulses for differentiating tissue excitation that yields a larger fat suppression that prior art water excitation methods. Proper balancing of the frequency offset and the pulse duration with a relative phase offset between the pulses leads to large-bandwidth pass- and stopbands for water and fat, respectively. The pulses can be applied with short, or even zero, interpulse delay, leading to substantial time savings in the imaging sequence.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01R 33/385 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des bobines de champ magnétique à gradient
The invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention concerns a method for separating cells of interest according to a specific marker expressed on their surface.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
23.
Pharmaceutical formulation for use in the treatment and/or prevention of restenosis
The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
24.
Actuating device for mechanical adjustment element of surgical implant
The present invention concerns an actuating device for actuating a mechanical adjustment element of surgical implant, said mechanical adjustment element allowing to modify the functional shape and/or the functional size of the surgical implant when actuated, said actuating device comprising transmission means linked with one end to the mechanical adjustment element and able to move the mechanical adjustment element when said transmission means are actuated, connecting means (7) mounted on the other end of the transmission means and able to actuate the transmission means, said connecting means (7) comprising coupling means and driving means (24) comprising complementary shaped coupling means, said driving means (24) being designed to be removable and fitted into the coupling means for moving the mechanical adjustment element by driving into movement a movable part of the connecting means (7).
A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical
A61F 5/00 - Procédés ou dispositifs d'orthopédie pour le traitement non chirurgical d'os ou articulationsDispositifs pour donner des soins
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
25.
Preparation of parental cell bank from foetal tissue
The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The invention relates to chemoembolization composition for anti-angiogenic agent delivery. The invention further relates to a method of preparing chemoembolization composition and to the use of chemoembolization composition in the method for treating solid tumor cancers.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
An annuloplasty ring system for repairing an atrioventricular cardiac valve includes an external support ring (2), an inner adjustable ring (4), a sliding pushing element (6) mounted between the external and inner rings (2, 4), and actuating element designed to control the pushing element (6). The pushing element (6) is designed, when actuated by the actuating element, to slide between the external ring (2) and the inner ring (4) and to press on the inner ring (4) by using the external ring (2) as a support, in such a way that a precise part of the inner ring (4) is deformed without modifying the perimeter of the inner ring (4).
brevets
